A Phase 3 interventional study of NVA237 and Tiotropium in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 76 sites in 15 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-04-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 18th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 21st registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 657 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 27th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 63rd registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compared the efficacy and safety of NVA237 with tiotropium in patients with moderate to severe COPD. Tiotropium belongs to the same drug class as NVA237.
This was a randomized, blinded, double-dummy, parallel-group 12-week study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients with chronic obstructive pulmonary disease (COPD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply and can be found in the study protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
Drug: NVA237 · Drug: Placebo to tiotropium · Drug: salbutamol/albuterol
Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
Drug: Tiotropium · Drug: Placebo to NVA237
NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
Tiotropium 18 μg once a day delivered via HandiHaler® device
Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
Placebo to NVA237 50 μg once a day delivered via SDDPI
Drug page: Albuterol
salbutamol/albuterol given as a rescue medication via inhaler when needed
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23hours 15min and 23 hours 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.
Time frame: Week 12
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid.
Time frame: Week 12
Transition Dyspnea Index (TDI) Focal Score After 4 Weeks and 12 Weeks of Treatment
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. ANCOVA model: TDI focal score = treatment + Baseline dyspnea index (BDI) + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
Time frame: Weeks 4 and 12
St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment
St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. ANCOVA model: SGRQ total score = treatment + baseline SGRQ score + baseline ICS use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region).
Time frame: Week 12
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 12 Week Treatment
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. Baseline mean daily, daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs. Only patients with a value at both baseline and post-baseline visits were included.
Time frame: Baseline and Day 1 to Week 12
Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 4
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. Trough assessments taken outside 22 h 45 min - 24 h 15 min are excluded from this analysis. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
Time frame: Day 1 and Week 4
Peak Forced Expiratory Volume in 1 Second (FEV1) During 5 Min to 4 Hours Post-dose, at Day 1 and Week 12
Spirometry was conducted according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded during first 4 hours post dose. ANCOVA model: Peak FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). Center is included as a random effect nested within region. This analysis excludes values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.
Time frame: 5 min to 4 hours post-dose at Day 1 and Week 12
Inspiratory Capacity (IC) at Each Time-point, by Visit
IC was measured with spirometry conducted according to internationally accepted standards. ANCOVA model: IC = treatment + baseline IC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
Time frame: (25 min, 1 h 55 min, 3 h 55 min, 23 h 40 min Day 1), (-20 min, 25 min, 23 h 40 min Week 4),(-20 min, 25 min, 1 h 55 min, 3 h 55 min, 23 h 40 min Week 12)
Forced Expiratory Volume in 1 Second (FEV1) at Each Time-point by Visit
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was analyzed using Analysis of Covariance (ANCOVA) model: FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
Time frame: (5,15,30 min, 1, 2,3,4 h, 23h 15 min and 23h 45 min postdose of Day 1), (-45, -15 min predose, 5,15,30 min, 1h, 23h 15 min and 23h 45 min postdose of Week 4), (-45, -15 min predose, 5,15,30 min, 1, 2, 3,4 h, 23h 15 min and 23h 45 min postdose of Week 12)
Forced Vital Capacity (FVC) at Each Time-point by Visit
Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. ANCOVA model: FVC = treatment + baseline FVC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
Time frame: (5,15,30 min, 1, 2,3,4 h, 23h 15 min and 23h 45 min postdose of Day 1), (-45, -15 min predose, 5,15,30 min, 1h, 23h 15 min and 23h 45 min postdose of Week 4), (-45, -15 min predose, 5,15,30 min, 1, 2, 3,4 h, 23h 15 min and 23h 45 min postdose of Week 12)
Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (5 Min-4 h) Post-dose
Forced Expiratory Volume in one second (FEV1) was measured with spirometry conducted according to internationally accepted standards. Area Under the Curve (AUC) is calculated using the trapezoidal rule using the existing FEV1 measurements (i.e., the missing FEV1 measurements are not interpolated). ANCOVA model: FEV1 AUC = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
Time frame: Day 1 and week 12
Event Free Rate at Weeks 4, 8 and 12 After Treatment
Event free rate was calculated as a percentage of participants who did not experience any moderate or severe COPD exacerbation leading to hospitalization/treatment with systemic corticosteroids/treatment with antibiotics. The event free rate reflects the percent of patients who did NOT have an exacerbation by 4, 8 and 12 weeks. Event-free rates are calculated at the end of the specified weeks (i.e. Day 29, Day 57 and Day 85) by the Kaplan Meier method.
Time frame: Weeks 4, 8 and 12
Mean Daily, Daytime and Nighttime (Combined) Symptom Scores Over the 12 Week Treatment Period
Participants completed eDiaries providing scores 0 to 3 for symptoms: Cough and wheeze (none, mild, moderate, severe); sputum volume (none, less than 5 mL, 5-25 mL, \>25 mL); sputum color (none, white-grey, yellow, green); lowest level of activity causing breathlessness (never or only when running, when walking uphill or upstairs, when walking on flat ground, at rest). Symptoms in the morning, for the previous night (no waking due to symptoms, woke up once due to symptoms, woke up more than once due to symptoms, woke up frequently or could not sleep due to symptoms). Symptoms experienced during the day that had prevented them for performing normal activities (not at all, a little, quite a lot, completely). The mean change from baseline in the total scores and in the individual scores was summarized by treatment. Only participants with a value at both baseline and post-baseline were included. Possible total scores 0-18 (night); 0-36 (day). A higher score means worsening of symptoms.
Time frame: 12 weeks
A total of 980 patients were screened, and 657 were randomized (327 to NVA237 and 330 to tiotropium).
| Milestone | NVA237 | Tiotropium |
|---|---|---|
| Started | 327 | 330 |
| Completed | 314 | 316 |
| Not completed | 13 | 14 |
| Withdrew: Adverse event | 7 | 5 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Abnormal test procedure result(s) | 2 | 0 |
| Withdrew: Inability to use device | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23hours 15min and 23 hours 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis) | 1.405 ± 0.0173 | 1.405 ± 0.0170 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority) | 1.398 ± 0.0154 | 1.393 ± 0.0149 |
Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. ANCOVA model: TDI focal score = treatment + Baseline dyspnea index (BDI) + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
| Units on a scale | NVA237 | Tiotropium |
|---|---|---|
| Week 4 (n= 289, 287) | 2.209 ± 0.2957 | 2.086 ± 0.2945 |
| Week 12 (n= 290, 285) | 1.990 ± 0.3169 | 2.178 ± 0.3159 |
St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. ANCOVA model: SGRQ total score = treatment + baseline SGRQ score + baseline ICS use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region).
| Units on a scale | NVA237 | Tiotropium |
|---|---|---|
| St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment | 39.42 ± 1.313 | 38.77 ± 1.306 |
A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. Baseline mean daily, daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs. Only patients with a value at both baseline and post-baseline visits were included.
| puffs | NVA237 | Tiotropium |
|---|---|---|
| Baseline | 4.09 ± 3.816 | 4.10 ± 3.791 |
| Day 1 to week 12 | 2.76 ± 2.768 | 2.84 ± 2.934 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. Trough assessments taken outside 22 h 45 min - 24 h 15 min are excluded from this analysis. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Day 1 (n=296, 288) | 1.385 ± 0.0124 | 1.386 ± 0.0122 |
| Week 4 (n=284, 280) | 1.416 ± 0.0163 | 1.416 ± 0.0160 |
Spirometry was conducted according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded during first 4 hours post dose. ANCOVA model: Peak FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). Center is included as a random effect nested within region. This analysis excludes values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Day 1 (n= 298, 292) | 1.575 ± 0.0123 | 1.520 ± 0.0121 |
| Week 12 (n= 290, 282) | 1.577 ± 0.0166 | 1.553 ± 0.0163 |
IC was measured with spirometry conducted according to internationally accepted standards. ANCOVA model: IC = treatment + baseline IC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Day 1, 25 min (n= 216, 214) | 2.378 ± 0.0263 | 2.300 ± 0.0253 |
| Day 1, 1 h 55 min (n= 212, 208) | 2.433 ± 0.0313 | 2.335 ± 0.0298 |
| Day 1, 3 h 55 min (n= 211, 207) | 2.343 ± 0.0325 | 2.309 ± 0.0317 |
| Day 1, 23 h 40 min (n= 213, 212) | 2.247 ± 0.0306 | 2.244 ± 0.0294 |
| Week 4, -20 min (n= 204, 204) | 2.231 ± 0.0342 | 2.240 ± 0.0326 |
| Week 4, 25 min (n= 201, 200) | 2.335 ± 0.0330 | 2.334 ± 0.0312 |
| Week 4, 23 h 40 min (n=199,205) | 2.284 ± 0.0362 | 2.289 ± 0.0347 |
| Week 12, -20 min (n= 205, 204) | 2.198 ± 0.0408 | 2.227 ± 0.0394 |
| Week 12, 25 min (n= 215, 205) | 2.292 ± 0.0397 | 2.280 ± 0.0385 |
| Week 12, 1 h 55 min (n= 213, 203) | 2.344 ± 0.0432 | 2.289 ± 0.0421 |
| Week 12, 3 h 55 min (n= 203, 207) | 2.313 ± 0.0395 | 2.275 ± 0.0374 |
| Week 12, 23 h 40 min (n= 208, 206) | 2.228 ± 0.0390 | 2.262 ± 0.0373 |
Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was analyzed using Analysis of Covariance (ANCOVA) model: FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Day 1, 5 min (n= 283, 278) | 1.382 ± 0.0087 | 1.331 ± 0.0086 |
| Day 1, 15 min (n= 282, 276) | 1.428 ± 0.0086 | 1.365 ± 0.0084 |
| Day 1, 30 min (n= 285, 281) | 1.442 ± 0.0104 | 1.379 ± 0.0102 |
| Day 1, 1 hour (n= 291, 286) | 1.482 ± 0.0111 | 1.419 ± 0.0109 |
| Day 1, 2 hours (n= 290, 286) | 1.517 ± 0.0127 | 1.454 ± 0.0126 |
| Day 1, 3 hours (n= 291, 285) | 1.527 ± 0.0141 | 1.471 ± 0.0138 |
| Day 1, 4 hours (n= 285, 281) | 1.490 ± 0.0137 | 1.448 ± 0.0135 |
| Day 1, 23 h 15 min (n= 289, 279) | 1.384 ± 0.0127 | 1.384 ± 0.0124 |
| Day 1, 23 h 45 min (n= 285, 278) | 1.381 ± 0.0139 | 1.379 ± 0.0140 |
| Week 4, -45 min (n= 280, 280) | 1.403 ± 0.0145 | 1.391 ± 0.0140 |
| Week 4, -15 min (n= 278, 279) | 1.388 ± 0.0146 | 1.393 ± 0.0139 |
| Week 4, 5 min (n= 277, 274) | 1.422 ± 0.0165 | 1.423 ± 0.0160 |
| Week 4, 15 min (n= 271, 270) | 1.459 ± 0.0163 | 1.466 ± 0.0159 |
| Week 4, 30 min (n= 272, 276) | 1.454 ± 0.0179 | 1.442 ± 0.0175 |
| Week 4, 1 hr (n= 280, 282) | 1.513 ± 0.0152 | 1.494 ± 0.0147 |
| Week 4, 23 h 15 min (n= 278, 276) | 1.422 ± 0.0171 | 1.417 ± 0.0167 |
| Week 4, 23 h 45 min (n= 274, 276) | 1.418 ± 0.0165 | 1.416 ± 0.0162 |
| Week 12, -45 min (n= 286, 279) | 1.394 ± 0.0176 | 1.380 ± 0.0174 |
| Week 12, -15 min (n= 283, 279) | 1.377 ± 0.0168 | 1.370 ± 0.0165 |
| Week 12, 5 min (n= 283, 271) | 1.430 ± 0.0182 | 1.411 ± 0.0181 |
| Week 12, 15 min (n= 275, 271) | 1.440 ± 0.0168 | 1.423 ± 0.0163 |
| Week 12, 30 min (n= 282, 278) | 1.461 ± 0.0168 | 1.432 ± 0.0163 |
| Week 12, 1 hr (n= 286, 279) | 1.500 ± 0.0164 | 1.475 ± 0.0160 |
| Week 12, 2 hours (n= 278, 277) | 1.507 ± 0.0173 | 1.484 ± 0.0169 |
| Week 12, 3 hours (n= 281, 279) | 1.506 ± 0.0179 | 1.484 ± 0.0175 |
| Week 12, 4 hours (n= 282, 280) | 1.473 ± 0.0187 | 1.462 ± 0.0183 |
| Week 12, 23 h 15 min (n= 276, 266) | 1.414 ± 0.0185 | 1.422 ± 0.0183 |
| Week 12, 23 h 45 min (n= 278, 276) | 1.415 ± 0.0183 | 1.420 ± 0.0180 |
Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. ANCOVA model: FVC = treatment + baseline FVC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Day 1, 5 min (n= 283, 278) | 2.925 ± 0.0249 | 2.874 ± 0.0247 |
| Day 1, 15 min (n= 282, 276) | 3.004 ± 0.0281 | 2.954 ± 0.0280 |
| Day 1, 30 min (n= 285, 281) | 3.036 ± 0.0277 | 2.991 ± 0.0274 |
| Day 1, 1 hour (n= 291, 286) | 3.036 ± 0.0298 | 3.006 ± 0.0296 |
| Day 1, 2 hours (n= 290, 286) | 3.061 ± 0.0314 | 3.029 ± 0.0312 |
| Day 1, 3 hours (n= 291, 285) | 3.135 ± 0.0334 | 3.111 ± 0.0329 |
| Day 1, 4 hours (n= 285, 281) | 3.073 ± 0.0305 | 3.046 ± 0.0301 |
| Day 1, 23 h 15 min (n= 289, 279) | 2.911 ± 0.0287 | 2.951 ± 0.0284 |
| Day 1, 23 h 45 min (n= 285, 278) | 2.942 ± 0.0279 | 2.951 ± 0.0279 |
| Week 4, -45 min (n= 280, 280) | 2.933 ± 0.0338 | 2.943 ± 0.0331 |
| Week 4, -15 min (n= 278, 279) | 2.879 ± 0.0356 | 2.898 ± 0.0345 |
| Week 4, 5 min (n= 277, 274) | 2.954 ± 0.0363 | 2.997 ± 0.0354 |
| Week 4, 15 min (n= 271, 270) | 3.021 ± 0.0378 | 3.058 ± 0.0372 |
| Week 4, 30 min (n= 272, 276) | 3.005 ± 0.0413 | 3.011 ± 0.0407 |
| Week 4, 1 hr (n= 280, 282) | 3.068 ± 0.0381 | 3.093 ± 0.0374 |
| Week 4, 23 h 15 min (n= 278, 276) | 2.982 ± 0.0364 | 3.013 ± 0.0359 |
| Week 4, 23 h 45 min (n= 274, 276) | 2.953 ± 0.0372 | 2.978 ± 0.0366 |
| Week 12, -45 min (n= 286, 279) | 2.889 ± 0.0416 | 2.905 ± 0.0415 |
| Week 12, -15 min (n= 283, 279) | 2.827 ± 0.0358 | 2.837 ± 0.0355 |
| Week 12, 5 min (n= 283, 271) | 2.929 ± 0.0403 | 2.953 ± 0.0403 |
| Week 12, 15 min (n= 275, 271) | 2.945 ± 0.0370 | 2.963 ± 0.0364 |
| Week 12, 30 min (n= 282, 278) | 2.963 ± 0.0374 | 2.982 ± 0.0367 |
| Week 12, 1 hr (n= 286, 279) | 3.011 ± 0.0377 | 3.009 ± 0.0373 |
| Week 12, 2 hours (n= 278, 277) | 3.008 ± 0.0390 | 3.012 ± 0.0386 |
| Week 12, 3 hours (n= 281, 279) | 3.014 ± 0.0404 | 3.018 ± 0.0399 |
| Week 12, 4 hours (n= 282, 280) | 2.964 ± 0.0404 | 2.977 ± 0.0398 |
| Week 12, 23 h 15 min (n= 276, 266) | 2.923 ± 0.0403 | 2.953 ± 0.0404 |
| Week 12, 23 h 45 min (n= 278, 276) | 2.929 ± 0.0436 | 2.955 ± 0.0434 |
Forced Expiratory Volume in one second (FEV1) was measured with spirometry conducted according to internationally accepted standards. Area Under the Curve (AUC) is calculated using the trapezoidal rule using the existing FEV1 measurements (i.e., the missing FEV1 measurements are not interpolated). ANCOVA model: FEV1 AUC = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.
| Liters | NVA237 | Tiotropium |
|---|---|---|
| Day 1 (n=298, 292) | 1.496 ± 0.0109 | 1.438 ± 0.0107 |
| Week 12 (290, 282) | 1.493 ± 0.0164 | 1.470 ± 0.0160 |
Event free rate was calculated as a percentage of participants who did not experience any moderate or severe COPD exacerbation leading to hospitalization/treatment with systemic corticosteroids/treatment with antibiotics. The event free rate reflects the percent of patients who did NOT have an exacerbation by 4, 8 and 12 weeks. Event-free rates are calculated at the end of the specified weeks (i.e. Day 29, Day 57 and Day 85) by the Kaplan Meier method.
| percentage of participants | NVA237 | Tiotropium |
|---|---|---|
| Week 4 | 95.6 (92.6 to 97.4) | 96.6 (93.7 to 98.1) |
| Week 8 | 92.9 (89.3 to 95.3) | 93.8 (90.4 to 96.1) |
| Week 12 | 90.2 (86.1 to 93.2) | 92.4 (88.8 to 95.0) |
Participants completed eDiaries providing scores 0 to 3 for symptoms: Cough and wheeze (none, mild, moderate, severe); sputum volume (none, less than 5 mL, 5-25 mL, \>25 mL); sputum color (none, white-grey, yellow, green); lowest level of activity causing breathlessness (never or only when running, when walking uphill or upstairs, when walking on flat ground, at rest). Symptoms in the morning, for the previous night (no waking due to symptoms, woke up once due to symptoms, woke up more than once due to symptoms, woke up frequently or could not sleep due to symptoms). Symptoms experienced during the day that had prevented them for performing normal activities (not at all, a little, quite a lot, completely). The mean change from baseline in the total scores and in the individual scores was summarized by treatment. Only participants with a value at both baseline and post-baseline were included. Possible total scores 0-18 (night); 0-36 (day). A higher score means worsening of symptoms.
| units on a scale | NVA237 | Tiotropium |
|---|---|---|
| Baseline | 7.21 ± 2.539 | 6.90 ± 2.627 |
| Day 1 to Week 12 | 5.96 ± 2.469 | 5.96 ± 2.531 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 | — | 11/327 (3.4%) | 48/327 (14.7%) |
| Tiotropium | — | 13/330 (3.9%) | 54/330 (16.4%) |
| Event | NVA237 | Tiotropium |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 3/327 | 6/330 |
| PneumoniaInfections and infestations | 2/327 | 2/330 |
| Ischaemic strokeNervous system disorders | 0/327 | 2/330 |
| Cardiac failureCardiac disorders | 1/327 | 0/330 |
| Diverticulum intestinalGastrointestinal disorders | 1/327 | 0/330 |
| Non-cardiac chest painGeneral disorders | 1/327 | 0/330 |
| CellulitisInfections and infestations | 1/327 | 0/330 |
| Lobar pneumoniaInfections and infestations | 1/327 | 0/330 |
| Femur fractureInjury, poisoning and procedural complications | 1/327 | 0/330 |
| Spinal cord injury cervicalInjury, poisoning and procedural complications | 1/327 | 0/330 |
| Event | NVA237 | Tiotropium |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 48/327 | 54/330 |
| Age, Continuous(Years) | NVA237 | Tiotropium | Total |
|---|---|---|---|
| Mean | 63.2 ± 7.98 | 63.7 ± 8.02 | 63.5 ± 8.00 |
| Sex: Female, Male(Participants) | NVA237 | Tiotropium | Total |
|---|---|---|---|
| Female | 90 | 82 | 172 |
| Male | 237 | 248 | 485 |
The record gives a start of Jun 2012, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →